Physician profile
Anne Schroeder
NPI 1902987845
$1,967.51
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $913 · 2020: $849 · 2021: $83.73 · 2024: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $121.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $500.00 | 2020 | |
| Sun Pharmaceutical Industries INC. | $217.67 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $203.92 | 2019-2021 | |
| Dompe US, INC. | $194.94 | 2019-2020 | |
| Hoffmann-La Roche Limited | $136.30 | 2019 | |
| Aerie Pharmaceuticals, INC. | $131.29 | 2019-2020 | |
| Alcon Vision LLC | $121.84 | 2024 | Hydrus Microstent |
| Shire North American Group INC | $99.92 | 2019 | |
| Novartis Pharmaceuticals Corporation | $93.39 | 2019-2020 | |
| Allergan, INC. | $90.60 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $78.36 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $53.30 | 2019-2020 | |
| Johnson & Johnson Surgical Vision, INC. | $26.40 | 2019 | |
| Eyepoint US, INC. | $19.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Schroeder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.